Plus Therapeutics announced on December 3, 2024, the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. This agreement secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda.
This continuing agreement builds on the company's recently announced partnership with SpectronRx, reflecting a comprehensive supply chain strategy. The goal is to establish a scalable, end-to-end supply chain.
The expanded supply chain is designed to meet the demands of late-stage clinical trials and future commercial needs. This ensures the sustained development and potential commercialization of Rhenium (186 Re) Obisbemeda.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.